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Abstract
Background: Rubinstein-Taybi Syndrome (RSTS, MIM 180849) is a rare congenital disorder
characterized by mental and growth retardation, broad and duplicated distal phalanges of thumbs
and halluces, facial dysmorphisms and increased risk of tumors. RSTS is caused by chromosomal
rearrangements and point mutations in one copy of the CREB-binding protein gene (CREBBP or
CBP) in 16p13.3. To date mutations in CREBBP have been reported in 56.6% of RSTS patients and
an average figure of 10% has ascribed to deletions.
Methods: Our study is based on the mutation analysis of CREBBP in 31 Italian RSTS patients using
segregation analysis of intragenic microsatellites, BAC FISH and direct sequencing of PCR and RT-
PCR fragments.
Results: We identified a total of five deletions, two of the entire gene and three, all in a mosaic
condition, involving either the 5' or the 3' region. By direct sequencing a total of 14 de novo
mutations were identified: 10 truncating (5 frameshift and 5 nonsense), one splice site, and three
novel missense mutations. Two of the latter affect the HAT domain, while one maps within the
conserved nuclear receptor binding of (aa 1–170) and will probably destroy a Nuclear Localization
Signal. Identification of the p.Asn1978Ser in the healthy mother of a patient also carrying a de novo
frameshift mutation, questions the pathogenetic significance of the missense change reported as
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recurrent mutation. Thirteen additional polymorphisms, three as of yet unreported, were also
detected.
Conclusion: A high detection rate (61.3%) of mutations is confirmed by this Italian study which
also attests one of the highest microdeletion rate (16%) documented so far.
Background
Rubinstein-Taybi syndrome (RSTS; MIM 180849) is a
congenital disorder characterized by growth retardation
and psychomotor developmental delay, broad and dupli-
cated distal phalanges of thumbs and halluces, and a wide
range of typical dysmorphic features. Facial dysmorphol-
ogy includes down-slanted palpebral fissures, broad nasal
bridge, beaked nose and micrognathia [1]. In addition,
patients with RSTS have an increased, although not well
documented, risk of tumor formation [2,3]. RSTS was
shown to be associated with microdeletions and point
mutations in the gene encoding the CREB-binding pro-
tein (CREBBP, also known as "CBP"), located in 16p13.3
[4]. CREBBP is a transcriptional coactivator and possesses
acetyltransferase activity on lysine residues of histones
and nonhistone proteins [5]. CREBBP partecipates in
basic cellular functions, including growth, differentiation,
DNA repair and apoptosis, regulating the expression of
many genes [6]. The mutations found in RSTS patients
vary from point mutations to relatively large microdele-
tions, which remove the entire gene, attesting that hap-
loinsufficiency of this dosage-sensitive gene is the
ultimate cause of the syndrome. More precisely, studies of
patients with missense and splice-site mutations that
affect only the histone acetyl transferase (HAT) domain of
CREBBP demonstrated that loss of HAT activity is suffi-
cient to cause the syndrome [7,8]. The related p300 pro-
tein, which is encoded by the EP300 gene on chromosome
22q13.2, shares homology with CREBBP and accordingly
serves as a transcriptional coactivator endowed with a
HAT domain [9]. Mutations of EP300 have been recently
reported in a small subset (3.3%) of RSTS patients [10].
This figure and the low detection rates (from 40% to
56.6%) of CREBBP gene assessed by all mutations studies
of RSTS patients suggest that other candidate genes might
contribute to the pathogenesis of this syndrome [4,10-
12]. We recruited 31 patients with consistent RSTS clinical
diagnosis and we tested them by microsatellite segrega-
tion analysis, FISH, RT-PCR and direct sequencing to find
mutations of the CREBBP  gene. This multimethod
approach allowed us to identify five deletions and 14
point mutations, accounting for the highest (61.3%)
mutation rate so far assessed. Particularly FISH analysis
was instrumental for detecting even subtle microdeletions
proving to be a method suitable more than mutation
analysis to disclose low level mosaic conditions.
Methods
Subjects
We analysed samples of 31 unrelated patients sent to our
laboratory with parental consent with the request of
genetic analysis for Rubinstein-Taybi syndrome. Studies
and procedures were in accordance with the ethical stand-
ards of the host institutions. The group consisted of 16
female and 15 male patients, aged 2 to 42 years. Clinical
diagnoses were established by different Centers and even-
tually confirmed by the coordinating clinical Center
(Dept of Pediatrics, University of Milan) based on clinical
records and photographs, when no pathogenetic muta-
tion could be found. Careful examination of the patients'
phenotypes was done, and the presence of malformations
and medical complications were confirmed or excluded.
Thirty subjects had a normal karyotype by Giemsa-trypsin
banding at 450-band resolution; patient 38 showed a 46,
XY, der(14)t(9;14)(p11.2;p11.2) karyotype.
Cell cultures, chromosome and interphase nuclei 
preparations
Phytohemagglutinin-stimulated peripheral blood lym-
phocytes were set up in culture from samples using Chro-
mosome Kit "Synchro" (Celbio) and modified RPMI
(Irvine Scientific) plus 5% fetal calf serum (Gibco). The
cultures were blocked with colchicine after 72 h. Chromo-
some preparations were obtained using a standard tech-
nique.
Clone preparations
BAC clones RP11 95J11, RP11 461A8 and RP11 566K11
were supplied by Mariano Rocchi [13]; BAC RP11 1072J2
was purchased from the CHORI BAC PAC Resource
Center (Oakland, USA). DNA was obtained starting from
a single colony grown in 4 ml of LB medium supple-
mented with 20 μg/ml chloramphenicol (Sigma) follow-
ing standard procedures.
FISH
BAC clones were labelled with digoxigenin-dUTP (Roche
Diagnostic) using a nick translation kit (Roche Diagnos-
tic). The FISH experiments were performed according to
standard procedures [14]. The chromosomes were coun-
terstained with DAPI in antifade (Vectashild), and then
visualised using a Leitz DM-RB microscope equipped for
DAPI and FITC/TRITC epifluorescence optics. The images
were captured by means of a CCD camera (HamamatsuBMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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3CCD Camera, C5810) and visualised using Highfish
software (Casti Imaging).
Analysis of FISH signals in mosaic condition
Almost 50 metaphases and 100 nuclei were scored for
each sample in order to establish the mosaic condition.
Only intact and undamaged nuclei free of cytoplasm were
analyzed. Nuclei with low signal intensities, diffuse sig-
nals, or absence of signals on both homolog chromo-
somes were considered to be hybridization failures and
were not scored. Two small focal (or paired) signals of the
same color and the same intensity, separated by a distance
of less than the area of one signal, were considered to be a
split signal from one chromosome. Interphase nuclei with
one large signal of the same color and increased intensity
of fluorescence with the absence of a second hybridiza-
tion signal in an interphase nucleus were considered to be
overlapping (or over-position) of two signals and were
not scored. Informative mosaic samples were defined as
those in which more than 5% of the nuclei had a repro-
ducible abnormal pattern of signals different from normal
chromosomal signals.
Microsatellite segregation analysis
Fluorescent genotyping was performed as previously
described [11]. The following fluorescently dye-labeled
chromosome 16p microsatellite markers: MS4, MS2 and
D16S3065 (from centromere to telomere) were used for
segregation analysis from parents to probands. Fluores-
cence detection was performed on an ABI 3100 sequencer.
ABI PRISM software (Genescan) was used for gel analysis.
RT-PCR analysis
RT-PCR analysis was performed as previously described
[11] for patients 14, 16, 20, 25, 28 and 29 for whom
mRNA was available.
Molecular analysis
The DNA sequencing of all coding exons of the CREBBP
gene was performed as previously described [11]. Twen-
tysix CREBBP PCR genomic fragments were amplified (see
Additional file 1). The DNA sequencing protocol was
updated for use with the BigDye Chemistry, Versions 2.0
and 3.1, and the ABI PRISM 310 and 377 Genetic analyzer
systems (Applied Biosystems, Darmstadt, Germany). If a
mutation or polymorphism was found, a second sequenc-
ing run was performed for confirmation. The origin of the
mutation or polymorphism, whether de novo or familial,
was established if parental DNA was available. Paternity
testing was not performed due to legal restrictions. The
Human Gene Mutation Database (HGMD) [15], recent
publications [8,10-12], and the dbSNP database [16] were
consulted to check whether sequence variations were pre-
viously reported or not. Missense mutations of patients 15
and 46 identified in this study were absent in 100 con-
trols, while that carried by patient 23 was absent in 50
controls.
Results
Clinical evaluation
Thirty-one Italian RSTS patients, whose main signs are
reported in Table 1, were carefully clinically analysed. Sex
ratio was F:M = 16:15. All patients had psychomotor/
mental retardation, which ranged from mild to severe in
17 cases. Microcephaly was evident in 20 (64.5%); a sub-
set (12 cases) accounting for 61.3% of RSTS patients man-
ifested poor growth. The main facial features were
specifically described and/or evident from photos (see
Figure 1) and the overall facial gestalt was absolutely typ-
ical in all but one patient. As reported in Table 1, the typ-
ical large thumb was evident in 93% (27/29 patients), and
in 11 cases it was also abducted; the hallux was large in
89% (26/29), and only in 4 cases it was valgus/varus.
Only 11 individuals had major malformations of internal
organs or limbs: congenital heart disease (patent ductus
arteriosus, ventricular/atrial septum defects, bicuspid
aorta) was reported in 6 of them, cryptorchid testes in 3,
coloboma of the optic nerve, renal hypoplasia, duodenal
malrotation and hexadactyly in one. In 5 patients super-
numerary nipples were evident. Only in two cases (pt 16
and 17) lacrimal ducts stenosis and sensorineural deaf-
ness (pt 14 and 38) were signaled. In case 46 the presence
of multiple epitheliomas was reported. In another single
case (pt 15) Perthe's disease was found.
Mutation analysis
We screened the 31 recruited patients for point mutations,
small deletions or insertions, and large deletions and
duplications of the CREBBP gene. First, by genotyping the
polymorphic intragenic repeats MS4, MS2 and D16S3065
[11] plus one SNP (c.5454G>A, [12]) we could identify
two deletions spanning the whole gene in patients 30 and
41. Both deletions affected the maternal chromosome.
Figure 2 shows for patient 30: (A) the haplotype recon-
struction attesting the lack of three maternally contributed
intragenic polymorphic loci; (B) FISH of the CREBBP
spanning BAC 1072J2 evidencing a signal of reduced
intensity on one chromosome 16. By means of FISH anal-
ysis we detected three additional deletions, all in a mosaic
condition. Two (pt 40, pt 66) affect the 5' of the gene,
while one (pt 38), spans mainly the central region of the
gene and its flanking 3' sequences. The last one is present
in a structurally rearranged karyotype (see subjects in the
methods section). The mosaic condition has been con-
firmed in two patients from which buccal smears were
available. Scoring of CREBBP specific signals on both lym-
phocytes (> 150 cells- metaphases and nuclei) and buccal
smears (>100 nuclei) gave comparable results in showing
an average 20% of deleted cells in both cases. A fraction of
30% deleted cells was estimated on the third case forBMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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whom a sample of 300 cells from peripheral blood was
scored. Current studies are in progress aimed to evaluating
the extent and boundaries of all the deletions. These data
will be reported elsewhere. A schematic view of the iden-
tified deletions mapped on the encompassed genomic
CREBBP region is shown in Figure 3.
Then we screened the remaining 26 patients for point
mutations by direct sequencing of 26 PCR genomic frag-
ments encompassing the complete coding sequence and
splice sites of CREBBP. We identified 14 sequence altera-
tions of pathogenic significance: all are listed in Table 2
and shown in Figure 4 in their location within exons
encoding different CREBBP domains. Although the iden-
tified mutations are distributed across the whole gene
without apparent hot-spots, six, including two missense
(p.Tyr1482Cys; p.Asp1543Tyr), and four truncating
mutations (p.Lys1239ValfsX14; p.Gly1479X;
p.Asp1543GlnfsX39; p.Pro1655CysfsX89) are clustered
within the HAT domain. Out of the remaining mutations,
which map outside the HAT domain, five of eight are pre-
dicted to lead to premature translation stops upstream of
the HAT region, thus indirectly spoiling its function. They
comprise p.Arg370X and p.Arg424X in the N-Terminal
Transactivation Domain (TAD), p.Gln662X in the CREB
Binding Domain and p.Gln1118ProfsX13 and
p.Arg1173X in the Bromodomain. The remaining three
mutations, p.Arg14Gly in the 5' Nuclear Receptor Binding
Domain, p.Ser2015AlafsX25 and p.Gln2022ArgfsX16 in
the C-Terminal TAD, do not affect the HAT domain at all.
a Patient 16 (negative for CREBBP mutations); b patient 17 (c.3715_3716delAA in CREBBP gene); c patient 46 (c.4627G>T in  CREBBP gene) Figure 1
a Patient 16 (negative for CREBBP mutations); b patient 17 (c.3715_3716delAA in CREBBP gene); c patient 46 (c.4627G>T in 
CREBBP gene). The typical RSTS facial features are visible in the three patients.
a b
cBMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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Twelve of 14 mutations are novel, while p.Arg370X has
been reported by several groups [8,10,11,17] and
p.Arg424X has been also recently described [12]. As to the
nine different single nucleotide substitutions they consist
of five nonsense (pts 24, 35, 11, 32 and 34), three mis-
sense (pts 23, 15 and 46) and one splice site mutation
(patient 20). Out of the five sequence alterations produc-
ing a frameshift in the reading frame, one is a 2 bp-dupli-
cation (pt 2) leading to the potential incorporation of 12
anomalous aminoacids, three are deletions sized 1, 2 and
7 nucleotides respectively (pts 22, 17 and 21) predicting
88, 13 and 15 anomalous aminoacids and one is a splice
site mutation (c.4728+1G>A) affecting IVS 28 donor site.
Analysis of this mutation with two different softwares, the
Splice Site Prediction by Neural Network (BDGP) [18]
and the SpliceView [19] indicated that the splice donor
site was suppressed (predicted scores = 0%) and a novel
candidate donor site 260 bp upstream the mutation was
activated. The SpliceView software, also detected a near
donor site, 104 bp upstream the splice mutation. We were
able to identify CREBBP transcripts from patient 20 also
including a smaller transcript, in addition to the normal
one (Figure 5). Direct sequencing of the anomalous tran-
script confirmed the activation of the nearest upstream
cryptic donor site predicted by the SpliceView software.
The frameshift produced by missplicing should lead to the
incorporation of 38 anomalous aminoacids.
All three missense changes, p.Arg14Gly (pt 23),
p.Asp1543Tyr (pt 46) and p.Tyr1482Cys (pt 15) were not
previously reported. They were established to have
occurred  de novo and were found absent in 50
(p.Arg14Gly) and in 100 (p.Asp1543Tyr and
p.Tyr1482Cys) healthy individuals, respectively. Further-
more all of them affect aminoacids that are highly con-
served both through evolution and in the related p300
(Figure 6) [20]. p.Arg14Gly in the 5' Nuclear Receptor
Binding Domain is predicted by PSORTII [21] to cause the
Table 1: Main clinical signs of the thirty-one Italian RSTS patients.
patient age sex microcephaly facial
features
PMR/MR large/bifid
abducted
thumb
hallux
large/bifid
hallux
valgus/varus
poor
growth
malformations CREBBP
mutation
46* 3 F - + + moderate +/- + -/- + + missense
42 18 F + + + +/+ + -/- + - deletion
32 4 F + + + +/- + +/- + - nonsense
34 2 M + + + moderate +/- - -/- + - nonsense
15 11 M + + + severe +/- + -/- + + missense
2 10 F + + + moderate +/- + -/- + - insertion
11 14 M + + + +/+ + -/- + + nonsense
17 14 F + + + +/- + -/- + + deletion
20 10 F + + + severe +/- + -/+ + - splice-site
mutation
21 7 M + + + +/+ + +/+ - + deletion
22 30 F + + + +/+ + -/- + - deletion
23 5 F - + + moderate +/+ + -/- - + missense
24 7 F - + + +/- + -/- + - nonsense
35 39 M - + + +/- + -/- + - nonsense
40 26 F + nd + severe +/- + nd + - mosaic del 5'
66 6 M - + + severe +/- + - - + mosaic del 5'
41 25 F + + + +/+ + -/- + - del mat
38 5 M - + + severe -/- + -/- - - mosaic del 3'
30 26 F + + + +/+ + -/- + - del mat
36 11 F - + + borderline +/- - -/- - - neg
39 13 M + + + -/- + -/- + + neg
43 11 M + + + servere nd nd nd - nd neg
44 21 M nd + + +/+ + -/- - - neg
1 9 M + + + moderate +/- - -/- - - neg
12 17 M + +/- + moderate +/- + -/- + - neg
14 6 F - + + moderate +/+ + -/- - + neg
16 8 M + + + moderate +/+ + -/+ + + neg
25 4 M - + + mild +/- + -/- - + neg
45 28 F nd + + moderate nd nd nd + nd neg
28 42 F + + + +/+ + -/- - - neg
29 37 M + + + +/- + -/- - - neg
*development of multiple epiteliomasBMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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destruction of a monopartite Nuclear Localization
Sequence (NLS) (Figure 7). This NLS is a typical monopar-
tite cluster of basic residues, with a conserved pattern
starting with Pro, followed by Lys or Arg in 3 out of 5 res-
idues (PKRAKLS) [22,23]. In addition the same software
predicted another central bipartite Nuclear Localization
Signal at 1591 (KKTNKNKSSISRANKKK). Both the NLSs
are highly conserved in mouse CREBBP and in p300 pro-
tein. p.Tyr1482Cys and the p.Asp1543Tyr are both in the
HAT domain. Finally we detected 18 CREBBP polymor-
phisms, including 12 single nucleotide polymorphisms
(SNPs) and a 3'UTR 1 bp-duplication (see Additional file
2). Three of the sequence variations have not been previ-
ously reported, including two intronic SNPs (c.3983-
22C>T, c.4560+14A>G) and the 3'UTR 7329+25dupC.
Conversely the sequence variation (c.5933A>G), was
reported in other patients with RSTS [11,12]. This substi-
tution, causing the p.Asn1978Ser change in a conserved
glutamine-rich region, downstream the HAT domain, has
been inherited by our patient 22 by his apparently normal
mother. The same patient was found to bear a de novo
truncating mutation in the exon upstream the
p.Asn1978Ser change (c.4963delC). We were able to
establish that both mutations occurred on the maternal
CREBBP deletion in patient 30 detected through: a genotyping of intragenic polymorphic markers (MS4, MS2, D16S3065 and  SNP c.5454G>A) in the available family members allowing haplotype reconstruction; b Double color FISH analysis showing a  signal of highly reduced intensity on one chromosome 16p for BAC 1072J2, specific for CREBBP (in red) Figure 2
CREBBP deletion in patient 30 detected through: a genotyping of intragenic polymorphic markers (MS4, MS2, D16S3065 and 
SNP c.5454G>A) in the available family members allowing haplotype reconstruction; b Double color FISH analysis showing a 
signal of highly reduced intensity on one chromosome 16p for BAC 1072J2, specific for CREBBP (in red). The residual hybridi-
zation is accounted for by the size of the genomic clone higher than the deleted region. The control subtelomeric 16q BAC 
566K11 shows a comparable signal on both chromosomes (in green).BMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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allele in a cis configuration (data not shown). Moreover
we detected the same nucleotide substitution in one of 50
controls analysed.
Discussion
By investigating 31 RSTS Italian patients using approaches
suitable to detect most types of CREBBP mutations we
identified  bona fide causative lesions in 19 subjects
(61.3%), a score slightly higher than that recently
reported [12]. Complementary application of FISH and
microsatellite analysis allowed us to detect five microdele-
tions, (which refined FISH characterization will be pub-
lished elsewhere) one of the highest microdeletion rate
(16%) documented so far, a finding that emphasizes pos-
sible underestimation of CBP  microdeletions in RSTS
patients [24-26]. Data achieved using realtime quantita-
tive PCR are consistent with this view [27].
Interestingly this is the first report describing mosaicism
for  CREBBP  deletions, indicating the contribution of
mitotic errors to this rare syndrome, that might exploit the
same breakpoints of the highly unstable region around
intron 2 of CREBBP evidenced in cancer [28-30]. It should
be noted that in one case (pt 38) the CREBBP mosaic dele-
tion is in the context of a rearranged karyotype, which
may account for the complex phenotype of the patient.
By sequencing all exons and splice sites of the CREBBP
gene, we identified on a total of 26 patients 14 different
mutations, only two of which have been described [8,10-
12,17]. Neither a predominant type of mutation nor clus-
tering of mutations within the CREBBP gene are apparent.
In agreement with previous studies, most mutations (11/
14, >78%) predict premature stop codons
[4,7,8,11,12,17,24]. Since RSTS is an autosomal domi-
nant trait, it can be assumed that truncating mutations are
disease causing mutations making superfluous to deter-
mine their de novo origin [10,11]. We also detected three
putative missense mutations, in which the pathogenic
role is much less clear. However, we were able to confirm
the de novo origin of all three missense mutations which
were found only once among 26 patients analysed and
were never observed in a 100 normal controls (50 in the
case of patient 23), ruling out that they are unreported
CBP polymorphisms. Moreover, when compared with the
murine CREBBP (Genbank: S66385) [31], which shows
95% identity across the whole 2441 aa length of the pro-
tein, all the three mutated residues were conserved (Figre
Mapping of the five deletions on the CREBBP genomic region Figure 3
Mapping of the five deletions on the CREBBP genomic region. Top: genomic organization of CREBBP with exons represented by 
black boxes and introns as connecting lines. The intragenic polymorphic loci are positioned across the gene. Middle: BAC 
clones used for preliminary FISH analysis, indicated by bars. Bottom: deletions are shown by thick lines; deletion ends contain-
ing the breakpoints, are represented by dashed lines.
D16S3065 MS2 MS4
ex31 ex1 ex2 ex12
RP11-1072J2
RP11-95J11
cen tel
RP11-461A8
Pt 38
Pt 30
Pt 41
Pts 40, 66
SNP c.5454G>ABMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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Location of the 14 causative CREBBP mutations found in this study Figure 4
Location of the 14 causative CREBBP mutations found in this study. Only exons are drawn to scale. The histone acetyl trans-
ferase domain and the plant homeodomain (PHD)-type zinc finger are indicated according to Kalkhoven et al. (2003), other 
domains according to Giles et al. (1997). Truncating mutations are in light-grey, missense mutations in dark-grey and the two 
previously reported mutations in italics.
Table 2: Fourteen causative CREBBP mutations detected by direct sequencing.
PATIENT MUTATION TYPE
23 Ex 1: c.40 A>G – p.Arg14Gly missense
24 Ex 4: c.1108C>T – p.Arg370X (Bartsch et al.2002) nonsense
35 Ex 5: c.1270C>T – p.Arg424X (Bartsch et al.2005) nonsense
11 Ex 10: c.1984C>T – p.Gln662X nonsense
2 Ex 17: c.3351_3352dupCC – p.Gln1118ProfsX13 insertion
32 Ex 18: c.3517C>T – p.Arg1173X nonsense
17 Ex 20: c.3715_3716delAA – p.Lys1239ValfsX14 deletion
34 Ex 27: c.4435G>T – p.Gly1479X nonsense
15 Ex 27: c.4445A>G – p.Tyr1482Cys missense
46 Ex 28: c.4627G>T – p.Asp1543Tyr missense
20 Ex 28: c.4728+1G>A splice-site mutation
22 Ex 30: c.4963delC – p.Leu1655CysfsX89 deletion
42 Ex 31: c.6043delA – p.Ser2015AlafsX25 deletion
21 Ex 31: c.6065_6071delAGCAGGC – p.Gln2022AgfsX16 deletion
In italics: mutations previously described.BMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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6). More generally their conservation, both phylogenetic,
from fruit fly to C. Elegans, and in the related p300 protein
highlights the functional importance of these residues in
the protein. Interestingly, two missense mutations are in
the HAT domain of CREBBP, where similar mutations
were shown to be sufficient to cause the RSTS phenotype
as they destroyed the acetyltransferase activity [7,8]. Fur-
thermore p.Tyr1482Cys (patient 15) is in the postulated
coenzyme A binding site (aminoacids 1459–1541). It
may not be fortuitous that the phenotypic presentation of
this patient strikingly overlaps the clinical presentation of
a second patient (20), carrying a splicing mutation affect-
ing the same domain. Application of RT-PCR allowed to
document the deleterious consequence of the splicing
mutation and to better interpret the patient's phenotype.
Indeed both patients 15 and 20 are affected by severe
mental retardation and complete absence of speech. The
third missense mutation, p.Arg14Gly, found in patient
23, is localised in the 5' end of the CREBBP protein, where
no other missense mutation has been reported. Aminoac-
ids from 1 to 100 are known to be responsible for the
Nuclear-Receptors binding (RAR, GR TXR) [32]. Moreo-
ver, according to the PSORTII software the resulting ami-
noacid change is predicted to disrupt a putative Nuclear
Localization Signal. Functional studies of this mutant pro-
tein are in progress to determine whether the predicted
NLS is necessary for the correct import of the protein into
the nucleus. It should be noted that patient 23 has a mild
phenotype, characterised by normal growth and absence
of microcephaly. This peculiar phenotype might be
accounted for by a reduced amount of CREBBP protein in
the nucleus because of impaired translocation of the
mutated product, rather than by a reduced binding to
Nuclear-Receptors.
In this study we detected the c.5933A>G leading to
p.Asn1978Ser change in patient 22, who carries also a de
novo truncating mutation (c.4963delC). We were able to
establish the cis phase of the two alterations on the mater-
nal allele. The same p.Asn1978Ser change was found in a
classic RSTS patient [11] and has been recently described
as a recurrent mutation, in a patient displaying an incom-
RT-PCR and bioinformatic analysis of the splice site mutation (c.4728+1G>A) of pt 20 Figure 5
RT-PCR and bioinformatic analysis of the splice site mutation (c.4728+1G>A) of pt 20. a RT-PCR of the CREBBP fragment 
including Ex 28 and 29 evidenced an additional smaller fragment (NC: normal control). b bioinformatic analysis with Splice Site 
Prediction [18] and the SpliceView [19]: the physiological donor site is in bold; the de-novo donor site activated is underscored. 
c schematic diagram of the misplicing predicted to occur in this patient with the cryptic donor site underscored. On the left 
electropherogram of the normal donor site; on the right the electropherogram attesting activation of the cryptic donor site.
NC
20
1.2
Kb
DONOR SITE:
EXON    INTRON    SCORE
ATG GTGAGG 88. 
AAG GTGATT 85.
GAG GTACAG 78.
AAA GTGAGT 87.
ATG GTGAGG 96 
GAG GTACAG 86
AAA GTGAGT 96 
Splice Site 
Prediction
SpliceView
Ex 28 Ex 29
AAGGTGATT GGCAGT
G>A
-104bp
WT Pt 20
a b
cBMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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plete RSTS phenotype [12]. We detected the same change
in our patient 22's healthy mother, and subsequently in
one of 50 additional control individuals who were stud-
ied: thus we infer it may be counted among CREBBP pol-
ymorphisms. Consistent with this view, the resulting
amino acid substitution, located outside the HAT domain,
affects an aminoacidic residue conserved in the mouse,
but not either in fruit fly and C. Elegans, or in p300 (Figure
6). Interestingly, a different change of the same residue
(p.Asn1978Asp) has been recently detected in an ovarian
and a breast tumour from unrelated individuals. Mutation
analysis in germline DNA which could be performed on
one of the two individuals showed the same sequence
alteration present in the tumours [33]. The authors
emphasised that the individual carrying the mutation in
the germline does not have the RSTS phenotype, as
expected of someone with a CREBBP mutation. All the
cumulated evidences indicate the affected CREBBP codon
as a highly polymorphic site, resulting in a aminoacidic
change which does not disrupt protein function suffi-
ciently to cause RSTS or to predispose to breast and/or
ovarian cancer. The overall data might help to interpret
this sequence change and to keep it into account in
genetic counselling.
Finally, we identified 13 additional sequence variations,
which can be added to the list of known CREBBP poly-
morphisms (see Additional file 2). Interestingly our
patients 16 and 25 share five different polymorphisms
inherited from their parents, in agreement with a recent
report [12]. Also our two families do not appear to be
related, but extended genetic histories were not available.
Conclusion
By combining different techniques we identified a
CREBBP mutation in 61.3% of RSTS cases, a mutation rate
higher than that of a recent study [12]. Intragenic micros-
atellite markers and FISH analysis enabled us to identify
one of the highest microdeletion rate (16%) documented
so far [24-26,34]. No significant correlation could be
established between different types of mutation and the
clinical presentation and significantly, the patients proved
negative to CREBBP  mutation screening (both point
mutations and deletions) represented the whole RSTS
phenotypic spectrum. The overall mutation rate attested
by our study and the fact that most CREBBP-negative
patients did not display a mild or borderline RSTS clinical
presentation provide further indirect evidence on the
involvement of genes other than CREBBP in the RSTS phe-
notype. Indeed, a few CREBBP lesions might have been
Conservation of amino acids that are predicted by ClustalW [20] to change by three missense mutations identified in this study Figure 6
Conservation of amino acids that are predicted by ClustalW [20] to change by three missense mutations identified in this 
study. a p.Arg14Gly of pt 23; b p.Tyr1482Cys of pt 15; c p.Asp1543Tyr of pt 46. The changed residues are conserved in man 
(GeneBank: Q92793), in mouse (GeneBank: P45481), in Drosophila melanogaster (DROM3A), in Caenorabditis elegans (CEL116) 
and in P300 protein.
a
b
c
p.Arg14Gly
p.Tyr1482Cys
p.Asp1543TyrBMC Medical Genetics 2006, 7:77 http://www.biomedcentral.com/1471-2350/7/77
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underestimated, as we ruled out silent exonic alterations
affecting splicing enhancers (in the CREBBP-negative
patients 14, 16, 25, 28 and 29), but not intronic altera-
tions affecting splicing as analysis at the RNA level was
precluded. Similarly the CREBBP promoter could not be
tested, as direct sequencing was attempted, but raised
technical problems. However the putatively missed
CREBBP alterations likely do not cover the whole fraction
of negative cases with a consistent RSTS phenotype. It may
be that a few of the screened patients will turn out, upon
a closer clinical examination, to have a different syndrome
that resembles RSTS. However, considering the larger set
of RSTS patients cumulatively ascertained by other
groups, yet mutations were not found in more than half
their patients as well [11,12]. The recent finding of only
three mutations of the CREBBP homologue p300 in a
series of 91 patients did not prompt us to screen this gene
in our much more restricted cohort [10]. However genetic
heterogeneity of RSTS patients is documented and lesions
in other genes encoding for proteins that interact with
CREBBP in various signal transduction pathways, should
be considered.
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